New research highlights significant insurance-driven hurdles, increasing second-line uptake of Fabhalta (Novartis), and strong physician interest in pipeline therapies including zaltenibart (Omeros), ...

Pharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined the fray, testing its Ultomiris in a subset of severely ill patients. A biologic medicine ...

NHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to access treatment with Alexion's Ultomiris, ahead of their counterparts in England and ...

The European Commission ((EC)) approved AstraZeneca's (AZN) Ultomiris to treat a rare central nervous system disorder. Read more here ...

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for chronic conditions. The strategic research collaboration will focus on the ...

When global asset teams come together in the early commercialisation phase – right through to phase 3 design and governance – they’re typically packed with highly experienced specialists, each ...

Find the latest AstraZeneca PLC (AZN.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

AZN AstraZeneca PLC 69.45 -2.36% Mkt cap 215.914B IndustryDrug Manufacturers—General SNY Sanofi 48.30 -2.05% Mkt cap 118.483B IndustryDrug Manufacturers—General GSK GSK plc 38.18 -0.86% Mkt cap ...

Xencor, Inc. OverviewBiotechnology / Healthcare Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment ...